

## СВЕДЕНИЯ

об официальном оппоненте по диссертации на соискание ученой степени кандидата медицинских наук Януса Григория Аркадьевича на тему «Методы молекулярно-генетической диагностики наследственного рака толстой кишки» по специальностям: 14.01.12 – онкология, 03.02.07 – генетика

Фамилия, имя, отчество	Место основной работы, должность	Ученая степень, ученое звание	Основные научные труды в рецензируемых научных изданиях за последние 5 лет, (не более 15 публикаций)
Орлов Сергей Владимирович	Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт медицинской приматологии», директор	Доктор медицинских наук, профессор, член-корреспондент РАН Шифр специальности: 14.01.12	<ol style="list-style-type: none"> <li>1. Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellempgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stöhr J, Kaiser R, Reck M. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Target Oncol.</i> 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2</li> <li>2. Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <i>JAMA.</i> 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.</li> <li>3. Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS. Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. <i>J Thorac Oncol.</i> 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.</li> <li>4. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet.</i> 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-</li> </ol>

6736(17)30123-X. Epub 2017 Jan 24. PMID: 28126333

5. Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2017 Apr 15;23(8):1937-1944. doi: 10.1158/1078-0432.CCR-15-3069. Epub 2016 Oct 10.
6. Kuevda EV, Gubareva EA, Krasheninnikov SV, Grigoriev TE, Gumenyuk IS, Sotnichenko AS, Gilevich IV, Karal-Ogly DD, Orlov SV, Chvalun SN, Redko AN, Alekseenko SN, Macciarini P. Evaluation of the influence of decellularization on the changes in biomechanical properties of primate lungs. *Dokl Biochem Biophys.* 2016 Sep;470(1):375-378. Epub 2016 Nov 6.
7. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. *Ann Oncol.* 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8.
8. Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. *Invest New Drugs.* 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.
9. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol.* 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.

- |  |  |  |  |
|--|--|--|--|
|  |  |  | <ol style="list-style-type: none"><li>10. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>J Clin Oncol</i>. 2015 Aug 20;33(24):2667-74. doi: 10.1200/JCO.2014.60.7317. Epub 2015 Jul 13.</li><li>11. Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebisch I, Palmer M, Reck M; LUME-Lung 1 Study Group. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. <i>Eur J Cancer</i>. 2015 Feb;51(3):317-26. doi: 10.1016/j.ejca.2014.11.015. Epub 2014 Dec 17.</li><li>12. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A. Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncol</i>. 2014 Apr;15(5):489-538. doi: 10.1016/S1470-2045(14)70029-4.</li><li>13. Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-III A Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. <i>J Clin Oncol</i>. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.</li><li>14. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized</li></ol> |
|--|--|--|--|

			<p>ABIGAIL study (BO21015). J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.</p> <p>15. Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2.</p>
--	--	--	--

Заместитель директора ФГБНУ «Научно-исследовательский институт медицинской приматологии» по научной работе  
к.м.н. О.И. Вышемирский

